Arcus Biosciences, Inc.
RCUS
$9.34
-$0.20-2.10%
| Weiss Ratings | RCUS - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | RCUS - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | RCUS - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.81 | |||
| Price History | RCUS - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -4.79% | |||
| 30-Day Total Return | -30.19% | |||
| 60-Day Total Return | -41.92% | |||
| 90-Day Total Return | -38.95% | |||
| Year to Date Total Return | -38.27% | |||
| 1-Year Total Return | -49.02% | |||
| 2-Year Total Return | -45.60% | |||
| 3-Year Total Return | -70.20% | |||
| 5-Year Total Return | -25.40% | |||
| 52-Week High % Change | -50.26% | |||
| 52-Week Low % Change | 5.88% | |||
| Price | RCUS - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $19.18 | |||
| 52-Week Low Price | $9.01 | |||
| 52-Week Low Price (Date) | Mar 10, 2025 | |||
| 52-Week High Price (Date) | Mar 15, 2024 | |||
| Valuation | RCUS - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 1.01B | |||
| Enterprise Value | 176.73M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -3.10 | |||
| Earnings Per Share Growth | -25.36% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 3.39 | |||
| Price/Book (Q) | 1.81 | |||
| Enterprise Value/Revenue (TTM) | 0.68 | |||
| Price | $9.34 | |||
| Enterprise Value/EBITDA (TTM) | -0.59 | |||
| Enterprise Value/EBIT | -0.57 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | RCUS - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 91.70M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | RCUS - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 510 694 6200 | |||
| Address | 3928 Point Eden Way Hayward, CA 94545 | |||
| Website | www.arcusbio.com | |||
| Country | United States | |||
| Year Founded | 2015 | |||
| Profitability | RCUS - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -120.15% | |||
| Profit Margin | -109.68% | |||
| Management Effectiveness | RCUS - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -17.26% | |||
| Return on Equity | -- | |||
| Income Statement | RCUS - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 258.00M | |||
| Total Revenue (TTM) | 258.00M | |||
| Revenue Per Share | $2.81 | |||
| Gross Profit (TTM) | -85.00M | |||
| EBITDA (TTM) | -300.00M | |||
| EBIT (TTM) | -310.00M | |||
| Net Income (TTM) | -283.00M | |||
| Net Income Avl. to Common (TTM) | -283.00M | |||
| Total Revenue Growth (Q YOY) | -16.13% | |||
| Earnings Growth (Q YOY) | -16.05% | |||
| EPS Diluted (TTM) | -3.10 | |||
| EPS Diluted Growth (Q YOY) | 5.08% | |||
| Balance Sheet | RCUS - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 978.00M | |||
| Cash Per Share (Q) | $10.67 | |||
| Total Current Assets (Q) | 1.02B | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 485.00M | |||
| Current Ratio (Q) | 4.496 | |||
| Book Value Per Share (Q) | $5.26 | |||
| Total Assets (Q) | 1.15B | |||
| Total Current Liabilities (Q) | 226.00M | |||
| Total Debt (Q) | 159.00M | |||
| Total Liabilities (Q) | 665.00M | |||
| Total Common Equity (Q) | 485.00M | |||
| Cash Flow | RCUS - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -84.00M | |||
| Cash from Financing (TTM) | 277.00M | |||
| Net Change in Cash (TTM) | 23.00M | |||
| Levered Free Cash Flow (TTM) | -41.25M | |||
| Cash from Operations (TTM) | -170.00M | |||
